All News
Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA
Dr. Rachel Tate uptoTate ( View Tweet)
Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F
Dr. Rachel Tate uptoTate ( View Tweet)
#abs1235 #acr22 @rheumnow
articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh
Olga Petryna DrPetryna ( View Tweet)
PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf
Dr. Rachel Tate uptoTate ( View Tweet)
🌟PSA vs RA 🌟
-UK cohort
PSA associated with:
👉⬆️ duration symptoms prior 2 referral
👉⬆️ interval between GP presentation and DX
👉⬇️DMARD commencement
👉⬇️ improvement in Dx activity @ 3/12
# We need to do better
#ACR22 Abst#1613 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
There is an association between the severity of skin and joint or axial disease, both at baseline and longitudinally, in pts presenting w/in 12 months of diagnosis of PsA. Abs 1511 #ACR22 @RheumNow https://t.co/PcVn6dITqU https://t.co/qxn3LBOW8d
Dr. Rachel Tate uptoTate ( View Tweet)
Even a 6 month delay in PsA diagnosis can lead to worse PROs on quality of life!
Likelihood of depression increased
Pts with PsA dx in <6 months reported better outcomes
Abs#1507 @RheumNow #ACR22 https://t.co/igCiH22CWi
Robert B Chao, MD doctorRBC ( View Tweet)
GUS (compared to RIS) uniquely binds both CD64+ myeloid cells and IL-23. CD64+ mononuclear phagocytes are enriched in the psoriatic skin and serve as the dominant IL-23 source. Does this lead to a change in clinical response? Abs 1487 #ACR22 @RheumNow https://t.co/P512bxSxRn
Dr. Rachel Tate uptoTate ( View Tweet)
‼️FAP (fibroblast activation protein)
PET-CT in PsA‼️
⚡️synovial and entheseal accum in PsA v HC
⚡️correlation of uptake with pain scores
⚡️IL-17A ⬇️ FAP, with arrest joint damage
⚡️persistent FAP - ⬆️ prog joint damage
❓new T2T in PsA❓
#ACR22 @RheumNow Abst#1602
Patricia Harkins DrTrishHarkins ( View Tweet)
How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves?
Survey shows <50% rheum collaborate with derm
Need updated EMRs and additional education
Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS
Robert B Chao, MD doctorRBC ( View Tweet)
⚡️PRESTO⚡️
📈PsA prediction tool in psoriasis
Risk of PsA at 1yr ⬆️:
👉younger
👉male
👉FHx Psoriasis
👉back stiffness
👉stiffness level
👉nail pitting
👉biologic use
👉⬆️ pain and global health
(AUC 72.3,95%CI 65.5,79.1)
#ACR22 @RheumNow Abst#1612
Patricia Harkins DrTrishHarkins ( View Tweet)
Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal antibodies and increased w/ ETN and SECU. Abs 1159 #ACR22 @RheumNow https://t.co/BtHMQ6apNI https://t.co/uZEYVQdiOU
Dr. Rachel Tate uptoTate ( View Tweet)
Ab1486 #ACR22
@Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA
Prediction base model w only traditional CV risks excellent (AUC 85.5)
Expanded model w damaged jts did not improve risk discrimination
@Rheumnow https://t.co/DMlOreW9zK
Eric Dein ericdeinmd ( View Tweet)
Ab1508 #ACR22 Enthesitis on PET/CT
20 untreated PsA pts w/ total body PET/CT
All 20 (100%) pts had entheseal inflammation
127/543 (~1/4) entheses showed inflammation
@RheumNow https://t.co/OQCBWW70bt
Eric Dein ericdeinmd ( View Tweet)
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow
Abstract #L02
💊Phase 3, randomized, placebo-controlled study
💉Biologic naive patients
✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi)
📍benefits sustained to week 52
🛑No new safety signals
Catherine Sims, MD DrCassySims ( View Tweet)
FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR
Dr. Rachel Tate uptoTate ( View Tweet)
Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs
Contrasting w/ data from real world TNF
Interesting data but small sample size & events N
https://t.co/gv8uvcThMD
Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg
Aurelie Najm AurelieRheumo ( View Tweet)
DANBIO registry: 1600+ pts RA, AxSpA, PsA
Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111)
Maintenance at 1yr:
>80%
> withdrawal in original IFX naive, but higher BL DA
Do second time switchers do better because of past switch experience?
Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz
Aurelie Najm AurelieRheumo ( View Tweet)
@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX
Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA.
Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity.
@RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
